Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6654439 | 0.82 | TLR8 (0.46) | CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL353025 | 0.80 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL21555491 | 0.79 | TLR8 (0.59) | CYP1A2TLR8METAP2ACHEKDM4E | |
| SCHEMBL7981849 | 0.79 | TLR7 (0.50) | TLR8METAP2KDM4EALDH1A1LMNA | |
| SCHEMBL7965466 | 0.78 | TLR8 (0.43) | TLR8METAP2ACHEKDM4EALDH1A1 | |
| SCHEMBL17561705 | 0.77 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6118671 | 0.77 | FBP1 (0.49) | CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL3295739 | 0.77 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL13543521 | 0.77 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6652856 | 0.77 | FGFR1 (0.41) | CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652032-B2 | 5-Thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2010-01-26 | — | — | US | disclosed |
| EP-2041153-B1 | NEW 5-THIOXYLOPYRANOSE DERIVATIVES | FOURNIER LAB SA (FR) | 2009-10-21 | — | — | EP | disclosed |
| US-20090118325-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-07 | — | — | US | disclosed |
| EP-2041153-A1 | NEW 5-THIOXYLOPYRANOSE DERIVATIVES | Laboratoires Fournier S.A. (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008007027-A1 | NEW 5-THIOXYLOPYRANOSE DERIVATIVES | LABORATOIRES FOURNIER S.A. (FR) | 2008-01-17 | — | — | WO | disclosed |
| US-6194396-B1 | ANTIALLERGENS; ANTIINFLAMMATION AGENTS; AUTOIMMUNE DISEASE; ANTISHOCK AGENTS; ANALGESICS; E.G., A 4 OR 7-PHENYLALKYLENE-OXYBENZIMIDAZOLE UNSUBSTITUTED OR SUBSTITUTED IN THE 1,2,3-POSITION WITH AN OXY, AMINO AND/OR THIO GROUP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| US-6083961-A | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES SUCH AS ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| EP-0774462-A1 | HETEROCYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118325-A1 | 5-Thioxylopyranose Compounds | STS, F2, CBR1 | CYP1A2 165/4885CYP2C9 77/4885CYP2C19 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.